Journal article
Individual drug sampling does not supplant the need for head-to-head trials in dermatology
Journal of the American Academy of Dermatology, Vol.62(6), pp.1062-1063
2010
DOI: 10.1016/j.jaad.2009.10.023
PMID: 20172624
Abstract
A growing body of evidence has highlighted several risks and benefits associated with in-office sampling of prescription medications. While use-testing dermatologic medications from a sample closet may benefit some patients, it seems that the stunning lack of head-to-head trials comparing therapeutic options is a much larger and more important impediment to our determination of when the increased cost of newer agents is justified by superior efficacy, safety, or tolerability. If physicians are to retain the critical autonomy to make independent prescribing decisions in concert with our individual patients, we must take responsibility to call for and generate the comparative data we need to evaluate therapeutic options.
Details
- Title: Subtitle
- Individual drug sampling does not supplant the need for head-to-head trials in dermatology
- Creators
- Jack S Resneck - Department of Dermatology, and Phillip R. Lee Institute for Health Policy Studies, University of California San Francisco School of Medicine, San Francisco, CaliforniaMarta VanBeek - Departments of Dermatology and Epidemiology, University of Iowa, Iowa City, Iowa
- Resource Type
- Journal article
- Publication Details
- Journal of the American Academy of Dermatology, Vol.62(6), pp.1062-1063
- DOI
- 10.1016/j.jaad.2009.10.023
- PMID
- 20172624
- NLM abbreviation
- J Am Acad Dermatol
- ISSN
- 0190-9622
- eISSN
- 1097-6787
- Publisher
- Mosby, Inc
- Language
- English
- Date published
- 2010
- Academic Unit
- Dermatology
- Record Identifier
- 9984025309802771
Metrics
23 Record Views